文献速递泌尿男性生殖肿瘤

前列腺癌新辅助运动治疗:一项1期、去中心化非随机对照试验

Neoadjuvant Exercise Therapy in Prostate Cancer: A Phase 1, Decentralized Nonrandomized ControlledTrial.
PubMed 文献 · JAMA Oncol · 2024-01-01

这项单中心1a期剂量探索试验在53例拟行手术的初治局限性前列腺癌男性中评估个体化中等强度跑步机步行运动治疗,采用远程实时监测和适应性持续重评估分配6个递增剂量水平(90–450分钟/周)。所有剂量水平均可行(≥75%相对运动剂量强度),未观察到严重不良事件,选择225分钟/周作为推荐的2期剂量;Ki67和PSA变化各剂量组置信区间多跨越0,未达统计学显著。

要点

  • 所有6个运动剂量水平均可行,≥75%患者达到相对运动剂量强度≥75%。
  • 未观察到严重不良事件,225分钟/周被选为推荐的2期剂量。
  • 各剂量组Ki67和PSA变化95%CI多跨越0,未达统计学显著。

核心结论

  • 这项非随机临床试验结果提示,新辅助运动治疗在局限性前列腺癌中可行、安全且具有前景的抗肿瘤活性。

研究设计与样本

  • 单中心1a期剂量探索试验,采用以患者为中心的去中心化平台,2019年6月至2023年1月纳入53例不活跃的初治局限性前列腺癌男性,计划行手术切除,数据于2024年6月分析。
  • 干预为个体化中等强度跑步机步行,6个递增剂量水平90–450分钟/周,使用适应性持续重评估分配,所有运动治疗通过远程实时监测进行。

主要发现

  • 可行性以相对运动剂量强度(REDI)评估,所有剂量水平均可行(≥75% REDI)。
  • Ki67平均(95%CI)变化:90分钟/周为5.0%(-4.3%至14.0%),150分钟/周为2.4%(-1.3%至6.2%),225分钟/周为-1.3%(-5.8%至3.3%),300分钟/周为-0.2%(-4.0%至3.7%),375分钟/周为-2.6%(-9.2%至4.1%),450分钟/周为2.2%(-0.8%至5.1%)。
  • PSA水平变化:90分钟/周为1.0 ng/mL(-1.8至3.8),150分钟/周为0.2 ng/mL(-1.1至1.5),225分钟/周为-0.5 ng/mL(-1.2至0.3),300分钟/周为-0.2(-1.7至1.3),375分钟/周为-0.7 ng/mL(-1.7至0.4),450分钟/周为-0.9 ng/mL(-2.4至0.7)。
  • 未观察到严重不良事件。

关键数值与推荐

  • 剂量水平可行性标准:≥70%患者达到REDI≥75%即认为可行。
  • 推荐2期剂量为225分钟/周(约每次治疗45分钟、每周5次)。

临床怎么用

  • 作者在结论中认为,新辅助运动治疗在局限性前列腺癌中可行、安全且具有前景的抗肿瘤活性,推荐2期剂量为225分钟/周。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Observational data have shown that postdiagnosis exercise is associated with reduced risk of prostate cancer death. The feasibility and tumor biological activity of exercise therapy is not known. OBJECTIVE: To identify recommended phase 2 dose of exercise therapy for patients with prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: This single-center, phase 1a dose-finding trial was conducted at a tertiary cancer center using a patientcentric, decentralized platform and included 53 inactive men with treatment-naive localized prostate cancer scheduled to undergo surgical resection between June 2019 and January 2023. Data were analyzed in June 2024. INTERVENTION: Six escalated exercise therapy dose levels ranging from 90 to 450 minutes per week of individualized, moderate-intensity treadmill walking, allocated using adaptive continual reassessment. All exercise therapy sessions were conducted remotely with real-time monitoring. MAIN OUTCOMES AND MEASURES: Feasibility was evaluated by relative exercise dose intensity (REDI). A dose level was considered feasible if 70% or more of patients achieved an REDI of 75% or greater. Activity end points were changes in tumor cell proliferation (Ki67) and plasma prostate-specific antigen levels between pretreatment and postintervention. Safety and changes in patient physiology were also assessed. RESULTS: A total of 53 men were enrolled (median [IQR] age, 61 [56-66] years). All dose levels were feasible (≥75% REDI). The mean (95% CI) changes in Ki67 were 5.0% (-4.3% to 14.0%) for 90 minutes per week, 2.4% (-1.3% to 6.2%) for 150 minutes per week, -1.3% (-5.8% to 3.3%) for 225 minutes per week, -0.2% (-4.0% to 3.7%) for 300 minutes per week, -2.6% (-9.2% to 4.1%) for 375 minutes per week, and 2.2% (-0.8% to 5.1%) for 450 minutes per week. Changes in prostate-specific antigen levels were 1.0 ng/mL (-1.8 to 3.8) for 90 minutes per week, 0.2 ng/mL (-1.1 to 1.5) for 150 minutes per week, -0.5 ng/mL (-1.2 to 0.3) for 225 minutes per week, -0.2 (-1.7 to 1.3) for 300 minutes per week, -0.7 ng/mL (-1.7 to 0.4) for 375 minutes per week, and -0.9 ng/mL (-2.4 to 0.7) for 450 minutes per week. No serious adverse events were observed. Overall, 225 minutes per week (approximately 45 minutes per treatment at 5 times weekly) was selected as the recommended phase 2 dose. CONCLUSIONS AND RELEVANCE: The results of this nonrandomized clinical trial suggest that neoadjuvant exercise therapy is feasible and safe with promising activity in localized prostate cancer. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03813615.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Jones LW, Moskowitz CS, Lee CP, et al. Neoadjuvant Exercise Therapy in Prostate Cancer: A Phase 1, Decentralized Nonrandomized ControlledTrial. JAMA Oncol. 2024. PMID: 39023900. doi:10.1001/jamaoncol.2024.2156

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。